Full-Life Expands Radiopharmaceutical Reach With $245m Focus-X Buyout

Area Attracting Investors

 
• By Dexter Jie Yan

Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.

acquisition deal
Asset acquisition helping Chinese biotechs gain traction in radiopharmaceuticals push • Source: Shutterstock

More from China

More from Focus On Asia